From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

Expert Review of Vaccines
Accepted author version posted online: 18 Jun 2018
A decade of experience with rotavirus vaccination in the United States–vaccine uptake, effectiveness, and impact
T Pindyck, JE Tate, UD Parashar
Abstract
Introduction: Prior to 2006, nearly every U.S child was infected with rotavirus by 5 years of age, and rotavirus was the leading cause of severe childhood gastroenteritis. In February 2006 and June 2008, the Advisory Committee on Immunization Practices recommended a live attenuated pentavalent rotavirus vaccine (RV5) and a monovalent rotavirus vaccine (RV1), respectively, for routine vaccination of infants in the U.S.
Areas covered: We reviewed U.S. data on coverage, vaccine effectiveness (VE), and vaccine impact from 2006-2017. National rotavirus vaccine coverage estimates increased since vaccine introduction but plateaued at 71%-75% in 2013-2015, a level 15%-20% lower than that of other routine childhood vaccines. Pooled VE of full series RV5 and RV1 against rotavirus-associated hospitalizations and emergency department visits were 84% (95% CI: 80%-87%) and 83% (95% CI: 72%-89%), respectively. Vaccine introduction resulted in a median decline in rotavirus-associated hospitalizations and ED visits of 80% and 57%, respectively, along with indirect protection of unvaccinated age groups and a decrease in health care costs. A biennial pattern in rotavirus detection emerged post-vaccine implementation.
Expert Commentary: The increasing use of rotavirus vaccines has substantially diminished the burden and changed the epidemiology of rotavirus disease in US children; efforts to increase rotavirus vaccine coverage should continue.

Emerging Infectious Diseases
01 Jul 2018, 24(7):1178-1187
Progress in Vaccine-Preventable and Respiratory Infectious Diseases-First 10 Years of the CDC National Center for Immunization and Respiratory Diseases, 2006-2016
A Schuchat, LJ Anderson, LE Rodewald, NJ Cox…
Abstract
The need for closer linkages between scientific and programmatic areas focused on addressing vaccine-preventable and acute respiratory infections led to establishment of the National Center for Immunization and Respiratory Diseases (NCIRD) at the Centers for Disease Control and Prevention. During its first 10 years (2006-2015), NCIRD worked with partners to improve preparedness and response to pandemic influenza and other emergent respiratory infections, provide an evidence base for addition of 7 newly recommended vaccines, and modernize vaccine distribution. Clinical tools were developed for improved conversations with parents, which helped sustain childhood immunization as a social norm. Coverage increased for vaccines to protect adolescents against pertussis, meningococcal meningitis, and human papillomavirus-associated cancers. NCIRD programs supported outbreak response for new respiratory pathogens and oversaw response of the Centers for Disease Control and Prevention to the 2009 influenza A(H1N1) pandemic. Other national public health institutes might also find closer linkages between epidemiology, laboratory, and immunization programs useful.